Track the 藥華藥 stock price and the full management transaction log of the company, a listed issuer based in Taiwan. Shares are quoted on the TW market, under the supervision of TWSE / TPEx (MOPS). Market capitalisation: €568.9bn. The latest transaction was reported on 31 July 2026 (Gift). Among the most active insiders: 詹青柳. Every trade is accessible without an account.
7
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 藥華藥 Buy (bullish), based on 8 analysts. Average price target: NT$1,312.
Fundamental score
Ranked 6,382 of 28,797 companies
65.6
score / 100
Value
40
Quality
91
FCF yld0.6%
Earn yld0.9%
EV/EBITDA·
ROE23%
Gross mgn89%
Net mgn32%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
藥華藥 is a company listed on the XTAI, specializing in the pharmaceutical sector. It focuses on the development and commercialization of innovative medications.